Home Cart Sign in  
Chemical Structure| 1235034-55-5 Chemical Structure| 1235034-55-5

Structure of A-1155463
CAS No.: 1235034-55-5

Chemical Structure| 1235034-55-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

A-1155463 is a highly selective BCL-XL inhibitor with an EC50 of 70 nM in Molt-4 cells.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of A-1155463

CAS No. :1235034-55-5
Formula : C35H32FN5O4S2
M.W : 669.79
SMILES Code : O=C(C1=C(CCCOC2=CC=C(C#CCN(C)C)C=C2F)SC(N3CC4=C(C=CC=C4C(NC5=NC6=CC=CC=C6S5)=O)CC3)=N1)O
MDL No. :MFCD29924714
InChI Key :SOYCFODXNRVBTI-UHFFFAOYSA-N
Pubchem ID :59447577

Safety of A-1155463

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
LP-9 62.5, 125, 250 nM 48 hours PMC8050302
MESO-1 62.5, 125, 250 nM 48 hours Induced apoptosis, 4-5.4-fold increase in Annexin V-positive cells PMC8050302
RKO 20 nM 72 hours Evaluated IC50 of Agerafenib, showing positive correlation with HSPA8 expression PMC4487849
Z-138 1000 nM 24 hours Evaluated the synergy between VEN and A1155463, showing a combination index (CI) of 4.96E-08, indicating strong synergy. PMC11261020
REC-1 1000 nM 24 hours Evaluated the synergy between VEN and A1155463, showing a combination index (CI) of 0.185, indicating strong synergy. PMC11261020
JEKO-1 1000 nM 24 hours Evaluated the synergy between VEN and A1155463, showing a combination index (CI) of 1.15E-03, indicating strong synergy. PMC11261020
MINO 1000 nM 24 hours To evaluate the effect of TH588 on Mino cell cycle, results showed TH588 caused G2/M phase arrest and apoptosis. PMC11261020
UPF1H 1000 nM 24 hours Evaluated the synergy between VEN and A1155463, showing a combination index (CI) of 0.003, indicating strong synergy. PMC11261020
MAVER-1 1000 nM 24 hours Evaluated the synergy between VEN and A1155463, showing a combination index (CI) of 0.009, indicating strong synergy. PMC11261020
HBL-2 1000 nM 24 hours Evaluated the synergy between VEN and A1155463, showing a combination index (CI) of 0.150, indicating strong synergy. PMC11261020
Human CD34+ cells 0.5 and 1.5 µM 24 hours Assess sensitivity to different cytotoxic drugs with BCL-XL inhibition, showing increased sensitivity to ER stress and pan-kinase inhibition. PMC6944703
GEO 20 nM 72 hours Evaluate the effect of BCL-XL siRNA on cell viability, results showed minimal change in survival of resistant cell lines. PMC4487849
SW1417 20 nM 72 hours Evaluate the effect of BCL-XL siRNA on cell viability, results showed significant reduction in survival of sensitive cell lines. PMC4487849
LS1034 20 nM 72 hours Evaluate the effect of BCL-XL siRNA on cell viability, results showed significant reduction in survival of sensitive cell lines. PMC4487849
Normal mesothelial cells (LP-9) 62.5, 125, 250 nM 48 hours To evaluate the effect of A-1155463 on normal mesothelial cells. Results showed A-1155463 had minimal effect on apoptosis in LP-9 cells. PMC8050302
MPM cells (MESO-1, MESO-4, JL-1, H2452, MSTO-211H, H28, H2052) 62.5, 125, 250 nM 48 hours To evaluate the effect of A-1155463 on MPM cell proliferation and apoptosis. Results showed A-1155463 significantly inhibited MPM cell proliferation and induced apoptosis. PMC8050302
SU-DHL-8 and RCK8 cell lines 446.4 nM and 167.4 nM Evaluate the sensitivity of BCL2Low NHL cell lines to A-1155463, showing that SU-DHL-8 and RCK8 were sensitive to A-1155463. PMC4670945
NHL cell lines 0-20μM 48 hours Evaluate the effect of BCL-XL selective inhibitor A-1155463 on the survival of NHL cell lines, showing that BCL2High cell lines were resistant to A-1155463 (EC50 45μM). PMC4670945
HEK293T cells 100 nM 24 hours To evaluate the effect of ACBI1 on SMARCA4 protein levels in HEK293T cells, results showed that ACBI1 treatment led to a reduction in SMARCA4 protein levels. PMC6588605

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice Patient-derived xenograft (PDX) models VEN (oral gavage), A1155463 (intraperitoneally) 10 mg/kg 4 days on/3 days off, for 2 weeks Evaluated the antitumor efficacy of the combination of VEN and A1155463, showing significant tumor growth inhibition even in VEN-resistant models. PMC11261020
NSG mice MESO-1 xenograft model Intraperitoneal injection 5 mg/kg Once daily for 23 days Combination therapy significantly suppressed tumor growth and enhanced apoptosis (increased cleaved caspase-3) PMC8050302
NSG mice MESO-1 xenograft model Intraperitoneal injection 5 mg/kg Once daily for 23 days To evaluate the efficacy of A-1155463 combined with HCQ in MPM xenografts. Results showed the combination treatment significantly suppressed tumor growth and induced apoptosis. PMC8050302

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.49mL

0.30mL

0.15mL

7.47mL

1.49mL

0.75mL

14.93mL

2.99mL

1.49mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories